參考文獻/References:
[1] Perry TA,Wang X,Gates L,et al.Occupation and risk of knee osteoarthritis and knee replacement: A longitudinal multiple-cohort study[J].Seminars in Arthritis and Rheumatism,2020,50(5):1006-1014.
[2] Sim HS,Ang K,How CH,et al.Management of knee osteoarthritis in primary care[J].Singapore Medical Journal,2020,61(10):512-516.
[3] Lee JY,Han K,Park YG,et al.Effects of education income and occupation on prevalence and symptoms of knee osteoarthritis[J].Scientific Reports,2021,11(1):1398-1403.
[4] Wallace IJ,Worthington S,Felson DT,et al.Knee osteoarthritis has doubled in prevalence since the mid-20th century[J].Proceedings of the National Academy of Sciences,2017,114(35):9332-9336.
[5] 王 斌,邢 丹,董圣杰,等.中國膝骨關節炎流行病學和疾病負擔的系統評價[J].中國循證醫學雜志,2018,18(2):134-142.
[6] Cross M,Smith E,Hoy D,et al.The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study[J].Annals of the Rheumatic Diseases,2014,73(7):1323-1330.
[7] Gilat R,Haunschild ED,Knapik DM,et al.Hyaluronic acid and platelet-rich plasma for the management of knee osteoarthritis[J].International Orthopaedics,2021,45(2):345-354.
[8] Cao P,Li Y,Tang Y,et al.Pharmacotherapy for knee osteoarthritis: Current and emerging therapies[J].Expert Opinion on Pharmacotherapy,2020,21(7):797-809.
[9] Primorac D,Molnar V,Rod E,et al.Knee osteoarthritis: A review of pathogenesis and state-of-the-art non-operative therapeutic considerations[J].Genes,2020,11(8):854.
[10] Bannuru RR,Osani MC,Vaysbrot EE,et al.OARSI guidelines for the non-surgical management of knee hip and polyarticular osteoarthritis[J].Osteoarthritis and Cartilage,2019,27(11):1578-1589.
[11] 時 克,王 茉,景莉君,等.基于斑馬魚毒/效同步評價的壯骨關節丸促骨骼發育作用與初步安全性研究[J].中國現代應用藥學,2019,36(2):164-167.
[12] 雷文淼.壯骨關節膠囊聯合玻璃酸鈉對創傷性踝關節炎患者滑膜液炎性因子的影響[J].陜西中醫,2017,38(1):82-83.
[13] 宋 蕾,袁曉美,畢亞男,等.壯骨關節丸對去勢所致雌性小鼠骨質疏松的治療作用[J].時珍國醫國藥,2020,31(2):307-310.
[14] 熊 殷,吳嘉瑞,張程亮.壯骨關節丸致肝損傷的研究進展[J].中南藥學,2019,17(12): 2084-2087.
[15] 李 外.壯骨關節丸致肝損傷文獻分析[J].中國中醫藥信息雜志,2017,24(5):122-123.
[16] Jorgensen L,Paludan AS,Laursen DR,et al.Evaluation of the cochrane tool for assessing risk of bias in randomized clinical trials:Overview of published comments and analysis of user practice in cochrane and non-cochrane reviews[J].Systematic Reviews,2016,5(1):80.
[17] 羅鈞君,駱勇全,閆惠鵬.壯骨關節丸聯合硫酸氨基葡萄糖膠囊治療氣滯血瘀型膝骨關節炎臨床研究[J].新中醫,2019,51(12):146-148.
[18] 胡 濱.壯骨關節膠囊治療膝關節骨性關節炎60例臨床研究[J].中國實用醫藥,2015,10(23):201-203.
[19] 王志彬,陳傳杰.壯骨關節膠囊配合透明質酸鈉注射液治療老年膝骨關節炎的療效[J].中國老年學雜志,2015,35(7):1835-1836.
[20] 張 瑞.壯骨關節膠囊配合透明質酸鈉注射液治療膝骨關節炎的療效觀察[J].臨床醫藥文獻電子雜志,2016,3(27):5483-5484.
[21] 王來福,侯芳麗.壯骨關節膠囊治療膝關節骨性關節炎98例療效觀察[J].北方藥學,2019,16(1):125-126.
[22] 張金龍,何延智.壯骨關節膠囊治療老年性膝骨關節炎的療效及安全性研究[J].中國老年保健醫學,2019,17(4):80-82.
[23] 王志強,許 丹,馮 創.壯骨關節膠囊聯合玻璃酸鈉治療膝骨關節炎的臨床研究[J].現代藥物與臨床,2021,36(1):126-129.
[24] 許 輝,肖漣波,康冰心,等.推拿手法治療膝骨性關節炎臨床療效及安全性Meta分析[J].陜西中醫,2019,40(12):1807-1813.
[25] 武永彪,石曉兵.膝骨性關節炎中醫治療現狀研究[J].陜西中醫,2019,40(4):543-545.
[26] 馬 鋒,馬敬祖,鞏 凡,等.壯骨關節膠囊對SD大鼠骨性關節炎并骨質疏松癥骨密度和雌激素受體表達的影響[J].中國臨床研究,2017,30(3):391-394.
[27] 郭群生,韓躍波,薛寶才.壯骨關節膠囊聯合玻璃酸鈉治療創傷性踝關節炎臨床研究[J].實用中醫藥雜志,2019,35(12):1519-1520.